Marinus Pharma (MRNS) Reports First Patient Enrollment in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus

Go back to Marinus Pharma (MRNS) Reports First Patient Enrollment in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus
(NASDAQ: MRNS) Delayed: 16.26 +1.00 (6.55%)
Previous Close $15.26    52 Week High $8.12 
Open $15.54    52 Week Low $1.02 
Day High $16.50    P/E N/A 
Day Low $15.43    EPS $0.00 
Volume 246,306